Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease

Lupus

Volumn 22, Issue 10, 2013, Pages 1070-1076

  Nandagudi, A ^a   Jury, E C ^b   Alonzi, D ^c   Butters, T D ^c   Hughes, S ^a   Isenberg, D A ^a,b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Fabry's disease; Gb3; SLE

Indexed keywords

AGALSIDASE BETA; AMITRIPTYLINE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLIZINE; HYDROXYCHLOROQUINE; IBUPROFEN; LOSARTAN; PREDNISOLONE; VALPROIC ACID;

ADULT; ARTHRALGIA; ARTICLE; CARDIOMYOPATHY; CASE REPORT; DYSPNEA; ENZYME REPLACEMENT; EXERCISE; FABRY DISEASE; FEMALE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE HYPERTROPHY; HETEROZYGOTE; HUMAN; HYPERTENSION; INCIDENCE; LOOSE FECES; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN;

FABRY'S DISEASE; GB3; SLE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; FABRY DISEASE; FEMALE; HEART FAILURE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84882986339     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313497116     Document Type: Article

References (44)

1. Sullivan DJ, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A. 1996 ; 93: 11865-118670
2. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005 ; 14: 683-686
3. Brigden W, Bywaters EG, Lessof MH, Ross IP. The heart in systemic lupus erythematosus. Br Heart J. 1960 ; 22: 1-16
4. Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford). 2006 ; 45 (Suppl 4): iv8 - iv13
5. Berg G, Bodet J, Webb K, et al. Systemic lupus erythematosis presenting as isolated congestive heart failure. J Rheumatol. 1985 ; 12: 1182-1185
6. Singh JA, Woodard PK, Dávila-Román VG, et al. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: A preliminary report. Lupus. 2005 ; 14: 137-144
7. Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis. 1990 ; 49: 627-629
8. Koopman WJ, Petri M Arthritis and allied conditions. Koopman WJ, ed. Lipppincott, Williams and Wilkins, PA, USA, 14th edition ; 2001: 1455-1479.
9. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005 ; 112: 3337-3347
10. Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms. Autoimmun Rev. 2006 ; 5: 101-105
11. Bruce IN. Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol. 2005 ; 19: 823-838
12. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 1997 ; 145: 408-415
13. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 ; 46: 1019-1027
14. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996 ; 93: 1579-1587
15. Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000 ; 9: 406-412
16. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: A transesophageal echocardiographic study. Stroke. 2005 ; 36: 592-596
17. Veres K, Lakos G, Kerényi A, et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus. 2004 ; 13: 423-427
18. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Throm Res. 2004 ; 114: 593-595
19. Ranzolin A, Bohn JM, Norman GL, et al. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction [in English and Portuguese]. Arq Bras Cardiol. 2004 ; 83: 141-144-137-140
20. Keating RJ, Bhatia S, Amin S, Williams A, Sinak LJ, Edwards WD. Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr. 2005 ; 18: 981-981
21. Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: A report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004 ; 33: 336-351
22. Saussine A, Loriot MA, Picard C, et al. Chloroquine cardiotoxicity in long-term lupus therapy in two patients [in French]. Ann Dermatol Venereol. 2009 ; 136: 530-535
23. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006 ; 44: 173-175
24. August C, Holzhausen HJ, Schmoldt A, Pompecki R, Schroder S. Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med (Berl). 1995 ; 73: 73-77
25. Cervera A, Espinosa G, Font J, Ingelmo M. Cardiac toxicity secondary to long term treatment with chloroquine. Ann Rheum Dis. 2001 ; 60: 301-301
26. Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999 ; 81: 221-223
27. Ratliff NB, Estes ML, Myles JL, Shirey EK, McMahon JT. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med. 1987 ; 316: 191-193
28. Sanmartí R, Gómez-Casanovas E, Solé M, et al. Prevalence of silent amyloidosis in RA and its clinical significance. J Rheumatol. 2004 ; 31: 1013-1014
29. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967 ; 276: 1163-1167
30. Das AM, Naim HY. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Adv Clin Chem. 2009 ; 49: 57-71
31. Mechtler TP, Stary S, Metz TF, et al. Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria. Lancet. 2012 ; 379: 335-341
32. Hoffmann B. Fabry disease: Recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009 ; 4: 21-21
33. Rahman P, Gladman DD, Wither J, Silver MD. Coexistence of Fabry's disease and systemic lupus erythematosus. Clin Exp Rheumatol. 1998 ; 16: 475-478
34. Majima K, Ishizaki T, Inoue T, et al. A case of Fabry's disease associated with lupus nephritis [in Japanese]. Nihon Jinzo Gakkai Shi. 1992 ; 34: 1189-1194
35. Rosenmann E, Kobrin I, Cohen T. Kidney involvement in systemic lupus erythematosus and Fabry's disease. Nephron. 1983 ; 34: 180-184
36. Arias Martínez N, Barbado Hernández FJ, Pérez Martín G, Pérez de Ayala C, Casal Esteban V, Vázquez Rodríguez JJ. Fabry's disease associated with rheumatoid arthritis. Multisystemic crossroads [in Spanish]. An Med Interna. 2003 ; 20: 28-30
37. Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis. 2007 ; 30: 365-369
38. Ames P, Margarita A, Alves J. Antiphospholipid antibodies and atherosclerosis: Insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009 ; 37: 29-35
39. Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol. 2007 ; 18: 608-615
40. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE - mechanisms and management. Nat Rev Rheumatol. 2012 ; 8: 214-223
41. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data. Lancet. 2009 ; 374: 1986-1996
42. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease. Clin Genet. 2004 ; 66: 158-165
43. Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008 ; 95: 163-168
44. Mellor HR, Neville DC, Harvey DJ, Platt FM, Dwek RA, Butters TD. Cellular effects of deoxynojirimycin analogues: Inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem J. 2004 ; 381 (Pt 3). 867-875